These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7541360)

  • 1. Tumor marker doubling time in patients with prostate cancer: determination of prostate-specific antigen and prostatic acid phosphatase doubling time.
    Akimoto S; Masai M; Akakura K; Shimazaki J
    Eur Urol; 1995; 27(3):207-12. PubMed ID: 7541360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase.
    Akimoto S; Inomiya H; Akakura K; Shimazaki J; Ito H
    Jpn J Clin Oncol; 1997 Aug; 27(4):258-62. PubMed ID: 9379515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Determination of tumor marker doubling time in the patients with prostate cancer relapsed from endocrine therapy].
    Akimoto S; Masai M; Kitagawa N; Nakamura T; Shimazaki J
    Nihon Hinyokika Gakkai Zasshi; 1993 Mar; 84(3):450-6. PubMed ID: 7685840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer.
    Matzkin H; Eber P; Todd B; van der Zwaag R; Soloway MS
    Cancer; 1992 Nov; 70(9):2302-9. PubMed ID: 1382828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between prostate-specific antigen, clinical stage, and degree of bone metastasis in patients with prostate cancer: comparison with prostatic acid phosphatase and alkaline phosphatase.
    Akimoto S; Furuya Y; Akakura K; Shimazaki J; Ito H
    Int J Urol; 1997 Nov; 4(6):572-5. PubMed ID: 9477186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice.
    Csapo Z; Brand K; Walther R; Fokas K
    J Urol; 1988 Nov; 140(5):1032-8. PubMed ID: 2459419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PSA doubling time in prostate cancer relapsed after endocrine therapy].
    Nakata S; Takahashi H; Takezawa Y; Kobayashi M; Matumoto K; Kosaku N; Kawashima K
    Nihon Hinyokika Gakkai Zasshi; 2000; 91(7-8):584-8. PubMed ID: 10965743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between prostatic acid phosphatase and prostate-specific antigen serum levels and prostatic volume in benign prostate hyperplasia. Pitfall on tumor markers assessment in primary prostatic cancer?
    Omacini S; Mione R; Barichello M; Santucci Delli Ponti U; Bolgan A; Contemori GP; Petracco S; Capitanio G; Donisi PM; Gion M
    Eur Urol; 1992; 21 Suppl 1():108-10. PubMed ID: 1385128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen and prostatic acid phosphatase in the detection of early prostate cancer and in the prediction of regional lymph node metastases.
    Wirth MP; Frohmüller HG
    Eur Urol; 1992; 21(4):263-8. PubMed ID: 1281102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
    Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
    Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of prostate-specific antigen and prostatic acid phosphatase in serum of patients with prostate cancer after orchidectomy.
    Dutkiewicz S; Stawarz B; Lypka A; Zieliński H
    Int Urol Nephrol; 1992; 24(4):409-16. PubMed ID: 1281145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous circadian fluctuations of prostate specific antigen and prostatic acid phosphatase serum activities in patients with prostatic cancer.
    Mannini D; Maver P; Aiello E; Corrado G; Vecchi F; Bellanova B; Marengo M
    Urol Res; 1988; 16(1):9-12. PubMed ID: 2449758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate].
    Morote Robles J; de Torres Mateos JA
    Arch Esp Urol; 1989; 42 Suppl 2():124-30. PubMed ID: 2484148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen and prostate acid phosphatase in the detection of early prostate cancer and the prediction of regional lymph node metastases.
    Wirth MP; Frohmüller HG
    Eur Urol; 1992; 22(1):27-32. PubMed ID: 1385142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of pelvic lymph node metastases by a prostate-specific antigen and prostatic acid phosphatase in clinical T3/T4M0 prostatic cancer.
    Waehre H; Wanderaas EH; Paus E; Fosså SD
    Eur Urol; 1992; 22(1):33-8. PubMed ID: 1385143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative value of prostate-specific antigen and prostatic acid phosphatase in diagnosis and management of adenocarcinoma of prostate. Ohio State University experience.
    Drago JR; Badalament RA; Wientjes MG; Smith JJ; Nesbitt JA; York JP; Ashton JJ; Neff JC
    Urology; 1989 Oct; 34(4):187-92. PubMed ID: 2477931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
    Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H
    Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gamma-seminoprotein--a new tumour marker in prostatic cancer? Results of a pilot study.
    Maier U; Simak R
    Br J Urol; 1990 May; 65(5):509-12. PubMed ID: 1693867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.
    Barichello M; Gion M; Bonazza A; Delli Ponti US; Bolgan A; Contemori GP; Barioli P; Capitanio G; Pecori B; Omacini S
    Eur Urol; 1995; 27(4):295-300. PubMed ID: 7544735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.